"Method For Determining Responsiveness To Prostate Cancer Treatment" in Patent Application Approval Process (USPTO 20230035403).
In: Cancer Vaccine Week, 2023-02-20, S. 45-45
serialPeriodical
Zugriff:
The method of claim 38, wherein the expression of the one or more prostate cancer biomarkers are evaluated before and after administering the therapeutically effective amount of the prostate cancer vaccine, and wherein a decrease in expression of the one or more prostate cancer biomarkers after administration of the prostate cancer vaccine is indicative of responsiveness to the prostate cancer vaccine. A method of treating prostate cancer in a subject, the method comprising: in a subject having a presence of one or more prostate cancer neoantigens comprising the amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 379, 381, 383, 385, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, fragments of the preceding sequences, or any combination thereof, in a sample from the subject, administering a therapeutically effective amount of a prostate cancer vaccine to the subject to thereby treat the prostate cancer. [Extracted from the article]
Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Method For Determining Responsiveness To Prostate Cancer Treatment" in Patent Application Approval Process (USPTO 20230035403).
|
---|---|
Zeitschrift: | Cancer Vaccine Week, 2023-02-20, S. 45-45 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6810 (print) |
Schlagwort: |
|
Sonstiges: |
|